| 24A652 |
Hikma Pharmaceuticals USA Inc., et al. v. Amarin Pharma, Inc., et al. |
Federal Circuit |
2024-12-31 |
Presumed Complete |
|
generic-drug hatch-waxman-act induced-infringement patent-infringement section-viii skinny-label |
Whether a generic drug manufacturer can be held liable for induced patent infringement when its label complies with the Hatch-Waxman Act's 'skinny lab… |
| 23-1320 |
GlaxoSmithKline, LLC, et al. v. Superior Court of California, Alameda County |
California |
2024-06-18 |
Denied |
Amici (1) |
can the consumer's home state assert specific per brand-name-manufacturer due-process generic-drug generic-drugs innovator-liability personal-jurisdiction preemption product-liability specific-jurisdiction warning-label-liability |
When a plaintiff alleges injury from the consumption of a generic drug |
| 22-37 |
Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC, et al. |
Federal Circuit |
2022-07-13 |
Denied |
CVSGAmici (5)Relisted (3) |
active-inducement fda-approval generic-drug generic-drugs hatch-waxman-act inducement-doctrine patent-infringement skinny-label |
Whether a generic drug manufacturer can be held liable for inducing infringement of a patent on a use that its FDA-approved label has expressly carved… |
| 20-1572 |
Ramon D. Johnson, II v. Novartis Pharmaceuticals Corporation, et al. |
Fifth Circuit |
2021-05-13 |
Denied |
Response WaivedRelisted (2) |
brand-name-liability brand-name-manufacturer FDA-approval generic-drug generic-drug-liability label-defect leave-to-amend preemption product-liability state-law-claims texas-presumption-of-no-liability unapproved-indication |
Whether a brand name drug manufacturer can be held liable for the defective label of a generic drug product |